Biotech Stocks Icon

Biotech Stocks

Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.

Recent Biotech Stocks Articles

Pharma Firms Duke It Out — Monday’s IP Market Recap

Pharmasset (VRUS) and Inhibitex (INHX) jump on positive hepatitis C drug news, and Vertex (VRTX) stock gets knocked back.

3 Reasons Why Alexion Is the Real Deal

Alexion's fundamentals and strength in a narrow category of drugs called biopharmaceuticals make ALXN a promising stock.

Medivation Shares Shoot Up on Prostate Cancer Treatment News

Medivation (MDVN) gains almost 140% Thursday on encouraging results for its prostate cancer treatment, and Dendreon (DNDN) is further battered.

Why Dendreon Is Aiming Prostate Drug Pitches to Consumers

Dendreon (DNDN) appears to be pulling out all the stops in an effort to restore at least some of the luster to its prostate cancer treatment Provenge.

Jump Into Walgreen on the Cheap; Ditch CVS

Walgreens (WAG) might actually benefit from a breakup with Express Scripts, and its standing as a Dividend Aristocrat doesn't hurt its case, either.

Top 5 Blue-Chip Stocks to Buy

There are two great sectors to play now -- and these are their finest blue-chip offerings. Pick up these shares before it's too late.

Amgen Bids for a Return to Favor

Amgen's (AMGN) third-quarter earnings, budget management and full-year outlook turn positive, boosting the company's market prospects.

Take the Cure — Sell J&J, Buy GSK

Johnson & Johnson and GlaxoSmithKline both have solid balance sheets, but GSK is poised to outperform its competitor.

9 Recession-Proof Biotech Stocks To Cure What Ails You

Health care stocks stay firm during a down economy and investors should consider up-and-coming biotech stocks like Alexion, Alkermes, Biogen and Cepheid.

Alexion Pharma Offers a Prescription for Profits

ALXN has been on a slow and steady climb, and is an excellent candidate for options income with covered calls.

Should You Buy the Dow — Pfizer

Pfizer's financials are decent, as is its lineup of drugs and personal care products, but the stock is fully valued.

Big Pharma Might Already Have Sights on Abbott Spinoff

Abbott's Humira is a dollar-printing temptation for several companies, but Pfizer's tofacitinib could change the rheumatoid arthritis drug landscape.

Should You Buy the Dow — Merck

Merck is a strong, old company with a good dividend -- it suits retirement accounts fine, but regular traders might want to keep their distance.

Is Abbott’s Spinoff the Beginning of a Trend?

A look at Abbott Labs' (ABT) breakup indicates splitting up may be good medicine for other diversified health care companies.

Johnson & Johnson, Forest Labs Will Make You Sick

Johnson & Johnson beat expectations but its profits were down; Forest Labs missed and has a plunging profit forecast. Investors should be wary of both pharma options.

Pfizer Crafting a Post-Patent Game Plan

As its Lipitor patent nears expiration, Pfizer considers new uses for Lyrica, its popular painkiller for fibromyalgia.

Biogen Idec Looking to Break Out

BIIB is setting up technically to run up in front of its Oct. 28 earnings announcement.

Should You Buy the Dow — Johnson & Johnson

Johnson & Johnson is protected by a diverse product line and sitting on a heap of cash. But JNJ stock already is on the high side of valuation, making this a tough pick.

7 Pharma Stocks to Sell, STAT

Pharmaceutical stocks are theoretically recession-proof. Still, not all pharma companies are equal. Here are seven clear losers to toss.